Long - term survival in a phase III , randomised study of topotecan versus paclitaxel in <font color="red">advanced_2</font> <font color="red">epithelial_2</font> <font color="red">ovarian_2</font> <font color="red">carcinoma_2</font> <font color="red">._2</font> 
<br>
<br> BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">advanced_2</font> <font color="red">epithelial_2</font> <font color="red">ovarian_2</font> <font color="red">cancer_2</font> <font color="red">who_2</font> <font color="red">had_2</font> <font color="red">failed_2</font> <font color="red">one_2</font> <font color="red">prior_2</font> <font color="red">platinum_2</font> <font color="red">-_2</font> <font color="red">based_2</font> <font color="red">regimen_2</font> <font color="red">._2</font> 
<br> PATIENTS AND METHODS <font color="red">Patients_2</font> <font color="red">with_2</font> <font color="red">bidimensionally_2</font> <font color="red">measurable_2</font> <font color="red">disease_2</font> were randomised to topotecan ( 1.5 mg / m(2)/day for 5 days ) or paclitaxel ( 175 mg / m(2)/day as a 3-h infusion ) every 21 days . Patients were eligible for treatment with the alternate therapy at third line . The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL)-C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) . 
<br> RESULTS <font color="red">A_1</font> <font color="red">total_1</font> <font color="red">of_1</font> <font color="red">226_2</font> <font color="red">patients_2</font> <font color="red">were_1</font> <font color="red">evaluable_1</font> <font color="red">for_1</font> <font color="red">response_1</font> <font color="red">._1</font> Demographic characteristics were similar in both treatment groups , as were results of the EORTC QOL-30 questionnaire . For the topotecan group , median time to progression was 18.9 weeks ( range < 1 to 92.6 + weeks ; 25% censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3 + weeks ; 12.3% censored ) ; P = 0.076 . At 4 years post - randomisation , median survival in the topotecan group was 63.0 weeks ( range < 1 to 238.4 + weeks ; 20.5% censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3 + weeks ; 12.3% censored ) ; P = 0.44 . 
<br> CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non - cumulative haematological toxicity . Non - haematological toxicity was generally mild for both groups . The long - term survival rate indicates substantial therapeutic benefit for this group of patients receiving topotecan at <font color="red">relapse_2</font> <font color="red">of_2</font> <font color="red">ovarian_2</font> <font color="red">cancer_2</font> <font color="red">._2</font>